NCT02978625 2026-03-18
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
Boston University
National Institutes of Health Clinical Center (CC)